Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
Shore N, Gazi M, Pieczonka C, Heron S, Modh R, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Bukkapatnam R, Dato P, Bevan-Thomas R, Cornell R, Wise DR, Hardwick MK, Hernandez RD, Rojahn S, Layman P, Hatchell KE, Heald B, Nussbaum RL, Nielsen SM, Esplin ED.
Shore N, et al. Among authors: esplin ed.
Eur Urol Oncol. 2023 Oct;6(5):477-483. doi: 10.1016/j.euo.2023.07.008. Epub 2023 Aug 12.
Eur Urol Oncol. 2023.
PMID: 37574391
Free article.